Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...
Recognizing the signs of mild cognitive impairment meant Di could start treatment earlier to help slow her Alzheimer's ...
The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...
Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster ...
Across 2 decades following the marketing of immunoglobulin, no new safety concerns appeared in pediatric adverse event ...
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data ...
Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO ...
Sarclisa (isatuximab) has been approved in the US since 2020, initially for relapsed/refractory multiple myeloma before ...
Racingnews365 on MSN
Antonelli reageert op FIA-maatregel tegen Mercedes en Red Bull
De FIA heeft een technical directive rondgestuurd die een trucje van Mercedes en Red Bull moet indammen. Kimi Antonelli vindt het niet zo erg.
Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...
In this video, Niraj Patel, MD, MS, discusses the monitoring of patients with primary immunodeficiency disease following treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results